Canadian Court Reaffirms $92.5 Million Damages Against Pfizer in Effexor Case

A Canadian court confirmed the C$125 million ($92.5 million) in damages Pfizer Canada Inc. paid Teva Canada Ltd. for unfairly delaying Teva’s introduction of a generic antidepressant (Teva Canada Ltd. v. Pfizer Canada, Inc., Can. Fed. Ct., T-1844-07, 5/26/17).

Barring further appeal, the Federal Court of Canada’s ruling reconfirmed the damages award after an appellate court found the original ruling in Teva’s favor improperly relied in part on hearsay evidence.

Reconsideration of the evidence based on the appellate court’s direction confirmed Ratiopharm Inc., later acquired by Teva, had enough generic Effexor XR (venlafaxine hydrochloride) to enter the Canadian ...